Ascendis Pharma A/S $ASND Shares Sold by Vestal Point Capital LP

Key Points

• Vestal Point Capital LP reduced its holdings in Ascendis Pharma A/S by 71.1% in the first quarter, owning 150,142 shares after selling 369,858 shares.
• Ascendis Pharma A/S reported a loss of ($0.93) per share, exceeding analysts' expectations of ($1.42), with revenue reaching $216.28 million against an anticipated $163.17 million.
• Fifteen analysts currently rate Ascendis Pharma A/S stock as a Buy, with a consensus price target of $243.36.

Vestal Point Capital LP cut its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 71.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 150,142 shares of the biotechnology company's stock after selling 369,858 shares during the quarter. Ascendis Pharma A/S comprises approximately 1.7% of Vestal Point Capital LP's investment portfolio, making the stock its 21st biggest position. Vestal Point Capital LP owned about 0.25% of Ascendis Pharma A/S worth $23,401,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth about $28,000. Brooklyn Investment Group increased its position in shares of Ascendis Pharma A/S by 332.9% during the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 273 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after purchasing an additional 664 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth about $174,000. Finally, Dearborn Partners LLC acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth about $203,000.

Ascendis Pharma A/S Stock Performance

Shares of ASND traded up $7.78 during midday trading on Friday, hitting $205.91. The company had a trading volume of 461,010 shares, compared to its average volume of 487,399. The company's 50-day simple moving average is $182.68 and its 200-day simple moving average is $167.87. The firm has a market capitalization of $12.60 billion, a P/E ratio of -39.91 and a beta of 0.39. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $207.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analysts' expectations of $163.17 million. Equities analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

ASND has been the subject of a number of recent analyst reports. Cantor Fitzgerald raised their price objective on Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Bank of America raised their target price on Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a "buy" rating in a report on Tuesday. Stifel Nicolaus raised their target price on Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a "buy" rating in a report on Friday, August 8th. UBS Group restated a "buy" rating and set a $307.00 target price (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, Wells Fargo & Company restated an "overweight" rating and set a $295.00 target price (up from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Fifteen investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $244.36.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.